FAS Wealth Partners Inc. Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

FAS Wealth Partners Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 921 shares of the medical equipment provider’s stock after purchasing an additional 41 shares during the period. FAS Wealth Partners Inc.’s holdings in Intuitive Surgical were worth $410,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Indiana Trust & Investment Management CO grew its stake in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares during the last quarter. Hoxton Planning & Management LLC grew its stake in Intuitive Surgical by 4.9% in the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 25 shares in the last quarter. First Affirmative Financial Network grew its stake in Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 26 shares in the last quarter. Advance Capital Management Inc. grew its stake in Intuitive Surgical by 3.8% in the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 27 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its stake in Intuitive Surgical by 0.5% in the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock worth $2,140,000 after purchasing an additional 27 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on ISRG shares. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Stifel Nicolaus increased their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Evercore ISI dropped their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Robert W. Baird increased their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Finally, Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Trading Up 1.0 %

Shares of ISRG traded up $4.96 during midday trading on Thursday, hitting $487.17. 939,631 shares of the company’s stock traded hands, compared to its average volume of 1,524,117. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $493.97. The firm’s fifty day moving average is $452.39 and its 200-day moving average is $413.17. The stock has a market capitalization of $172.80 billion, a price-to-earnings ratio of 87.94, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the firm earned $1.18 EPS. The firm’s revenue was up 14.5% on a year-over-year basis. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 396 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $486.88, for a total value of $192,804.48. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,680,761.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Desantis sold 396 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $486.88, for a total value of $192,804.48. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,680,761.28. The disclosure for this sale can be found here. Insiders have sold a total of 55,552 shares of company stock valued at $26,281,657 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.